Wuhan Yzy Biopharma Presents Clinical Trial Data of Tumor Drug at Cancer Conference

MT Newswires Live05-24

Wuhan Yzy Biopharma (HKG:2496) presented the data from an interim analysis of a phase II study of M701 at a poster session of the American Society of Clinical Oncologyâs annual meeting, a Friday filing on the Hong Kong bourse said.

M701 has been developed by the company for the treatment of malignant ascites caused by advanced epithelial solid tumors.

The study showed promising results in terms of efficacy and safety, according to the filing by the biotechnology firm.

Price (HKD): $7.45, Change: $, Percent Change: %

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2437031835?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-24 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2437031835","market":"nz","top_or_hot":-1,"title":"Wuhan Yzy Biopharma Presents Clinical Trial Data of Tumor Drug at Cancer Conference","media":"MT Newswires Live","content":"<html><body><p> Wuhan Yzy Biopharma (HKG:2496) presented the data from an interim analysis of a phase II study of M701 at a poster session of the American Society of Clinical Oncologyâs annual meeting, a Friday filing on the Hong Kong bourse said. </p><p>M701 has been developed by the company for the treatment of malignant ascites caused by advanced epithelial solid tumors. </p><p>The study showed promising results in terms of efficacy and safety, according to the filing by the biotechnology firm. </p><p>Price (HKD): $7.45, Change: $, Percent Change: %</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wuhan Yzy Biopharma Presents Clinical Trial Data of Tumor Drug at Cancer Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWuhan Yzy Biopharma Presents Clinical Trial Data of Tumor Drug at Cancer Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-24 20:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wuhan Yzy Biopharma (HKG:2496) presented the data from an interim analysis of a phase II study of M701 at a poster session of the American Society of Clinical Oncologyâs annual meeting, a Friday ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2437031835","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2437031835","pubTimestamp":1716554274,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Wuhan Yzy Biopharma  presented the data from an interim analysis of a phase II study of M701 at a poster session of the American Society of Clinical Oncologys annual meeting, a Friday filing on the Hong Kong bourse said. M701 has been developed by the company for the treatment of malignant ascites caused by advanced epithelial solid tumors. The study showed promising results in terms of efficacy and safety, according to the filing by the biotechnology firm. Price : $7.45, Change: $, Percent Change: %","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK1161":"生物科技","HKD":"尚乘数科","BK4588":"碎股","02496":"友芝友生物-B","BK4023":"应用软件","BK4526":"热门中概股"},"translate_title":"武汉友芝生物在肿瘤大会上展示肿瘤药物临床试验数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HKD":1,"02496":0.9},"content_text":"Wuhan Yzy Biopharma (HKG:2496) presented the data from an interim analysis of a phase II study of M701 at a poster session of the American Society of Clinical Oncologyâs annual meeting, a Friday filing on the Hong Kong bourse said. M701 has been developed by the company for the treatment of malignant ascites caused by advanced epithelial solid tumors. The study showed promising results in terms of efficacy and safety, according to the filing by the biotechnology firm. Price (HKD): $7.45, Change: $, Percent Change: %","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2437031835"}